# Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

> **NCT04413123** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bradley A. McGregor, MD** · enrollment: 60 (estimated)

## Conditions studied

- Papillary Renal Cell Carcinoma
- Unclassified Renal Cell Carcinoma
- Translocation Renal Cell Carcinoma
- Chromophobe Renal Cell Carcinoma
- Collecting Duct Renal Cell Carcinoma
- Renal Cell Carcinoma
- Unresectable Advanced Renal Cell Carcinoma
- Metastatic Ncc Renal Cell Carcinoma

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT04413123
- **Lead sponsor:** Bradley A. McGregor, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-05
- **Primary completion:** 2026-06-20
- **Final completion:** 2026-12-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04413123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04413123, "Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04413123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*